Takeda Drives Leading PAMES Study in Brazil Showing Improved Symptom Relief for People with Erosive Gastroesophageal Reflux Disease (GERD)

Takeda Drives Leading PAMES Study inTakeda Drives Leading PAMES Study in Brazil Showing Improved Symptom Relief for People with Erosive Gastroesophageal Reflux Disease (GERD) PR Newswire ZURICH, December 12, 2013 ®- First Head to Head Study Showed Tecta As Effective for Healing and Complete Remission of Erosive GERD with Significantly Higher Symptom [1]Relief After 8 Weeks compared to Esomeprazole - Takeda Pharmaceuticals International GmbH (Takeda) announced today ®results showing pantoprazole magnesium 40 mg (Tecta ) was as effective as esomeprazole 40 mg for achieving complete remission (defined as combined endoscopic healing and symptomatic relief) and the mucosal healing rate was high, whilst providing significantly higher symptom relief [1]after 8 weeks. Results of this Brazilian study, PAMES (Pantoprazole Magnesium x Esomeprazole), published today in the international medical journal, Alimentary Pharmacology and Therapeutics, provide further ®evidence to support the effectiveness of Tecta in the management of erosive GERD, a condition which affects 10-30% of people around the [2]world. Led by one of Brazil's principal medical research institutes, University of São Paulo Medical School, PAMES is the first head to head study which compares complete remission, healing and symptom relief of the proton- ®pump inhibitors (PPIs) pantoprazole magnesium 40 mg (Tecta ) with that [1]of esomeprazole in patients with erosive GERD.